and Cu(II) (6a, 7a, 8a, 8b and 9b) metal ions or can be cyclized to 1-benzothiazol-2-yl-3-methyl-1H-chromeno[4,3-c]pyrazol-4-one (3a) or 1-(6-chloropyridazin-3-yl)-3-methyl-1H-chromeno[4,3-c]pyrazol-4-one (3b). The crystal and molecularstructures of ligand 2a, its Cu(II) complexes 6a and 7a were determined by X-ray diffraction method. Cytotoxic activity of the ligands 2a and 2b and their complexes 4a
在这里,我们介绍了新的螯合配体1-苯并噻唑-2-基-5-(2-羟苯基)-3-甲基-1 H-吡唑-4-羧酸甲酯(2a)和1-(6-氯哒嗪-3-基)-5-(2-羟基苯基)-3-甲基-1- ħ吡唑-4-羧酸甲酯(图2b),在2 -甲基-4-氧代-4-反应得到ħ -苯并亚甲基-3-羧酸甲酯(1)与肼衍生物。这些配体2a和2b与Pt(II)(4a,4b),Pd(II)(5a,5b)和Cu(II)(6a,7a)形成固体配合物,8a,8b和9b)金属离子或可环化成1-苯并噻唑-2-基-3-甲基-1 H-苯并[4,3 - c ]吡唑-4-酮(3a)或1-(6 -氯哒嗪-3-基)-3-甲基-1 H-苯并[4,3 - c ]吡唑-4-酮(3b)。通过X射线衍射法测定了配体2a,其Cu(II)配合物6a和7a的晶体和分子结构。配体2a和2b及其配合物4a,4b,5a,还显示了图5a,6a,8a,8b和9b,以及对BAX和P53基因表达的调节。